A skilled CFO from the biotech industry has been appointed to oversee financial strategy and support Trevi Therapeutics, Inc.'s growth phase in New Haven, Conn. The company, listed on Nasdaq as TRVI, specializes in developing the experimental drug Haduvio™. This strategic move was announced on Dec. 4, 2025.